期刊文献+

支气管哮喘诱导痰嗜酸性粒细胞与最大呼气流速关系的研究 被引量:8

下载PDF
导出
摘要 目的:本研究对支气管哮喘急性发作期(中度)患者治疗前后最大呼气流速(PEF)与诱导痰嗜酸性粒细胞(EOS)计数变化对比,以及研究急性发作期诱导痰EOS计数与PEF(%)的相关性,为指导支气管哮喘的治疗提供敏感指标。方法:选取2011年3月至2013年3月在我院就诊的确诊为支气管哮喘急性期(中度)的患者60例,经沙美特罗替卡松治疗3个月前后进行肺功能PEF测定及诱导痰EOS计数测定。结果:哮喘患者急性发作期治疗后较治疗前PEF%增加(P<0.05);哮喘患者急性发作期治疗后较治疗前EOS计数降低;支气管哮喘急性发作EOS计数与PEF(%)有相关性(r=-0.728,P<0.01),呈负相关。结论:根据EOS计数变化能评估哮喘患者的治疗疗效以及联合使用EOS计数、PEF%对支气管哮喘患者的病情程度进行评估及对治疗疗效进行判定及跟踪。
出处 《河北医学》 CAS 2014年第2期294-296,共3页 Hebei Medicine
  • 相关文献

参考文献6

  • 1Wever AM ,Wever Hess J, Hensgens HE, et al.Serum eosi- nophilecationic protein (ECP) in chronic asthma relationship tospiromelr flow vollme curres and exacerbations[ J] .Respir Med, 1994,8(8) :613-621.
  • 2Pin I, Gibson PG, Kolendowicz R, ct al. Use of induced sputum cell counts to investigate airway inflammation in asthma[J].Thorax,1992, 47 (1) : 25-29.
  • 3Rosi E , Ronchi MC , Grazzini M , et al. Sputum analysis bronchial hytoperresponsivness and airway function in asthma : Results of a factor analysis [ J ]. Allergy Clin Immunol, 1999,103:232-237.
  • 4中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南.中华结核和呼吸杂志,2008,:250-250.
  • 5Pizziehini E, Pizzichini MM , Ef thimiadis A, et al. Intodices of airway inflammation in induced sputum: reproteducibility and validity of cell and fluid-phase measuretoments[ J] .Am Respir Crit Care Med, 1996,154:308-317.
  • 6Pavord ID, Pizzichini MM, Pizzichini E, et al.The use of in- duced sputum to investigate inflammation [ J ].Thorax, 1997, 47:489-501.

共引文献97

同被引文献69

  • 1贺彬,彭向东.治疗支气管哮喘中药研究进展[J].中南药学,2005,3(5):315-318. 被引量:7
  • 2王家珍,吕祖铭.基质金属蛋白酶及其抑制物在支气管哮喘中的研究进展[J].中国药房,2006,17(1):65-67. 被引量:6
  • 3高学敏.中药学[M].北京:中国中医药出版社,2007:1,21,23,24,26,28.
  • 4Taherian M,Razavi AR,Izad M.The role of interleukin-23in stability of in vitro T helper-17 cells[J].Iran Allergy Asthma Immunol,2014,13(2):131-137.
  • 5American Thoracic Society, European Respiratory Society. ATS/ ERS recommendations for standardized procedures for the on line and off line measurement of exhaled lower respiratory nitric oxide and nasal nittic oxide, 2005 [ J 1. Am J Respir Crit Care Med, 2005,171 (8) :912-930.
  • 6Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again [ J 1. Immunol Rev, 2011,242 ( 1 ) :220-232.
  • 7Nakagome K, Nagata M. Pathogcnesis of airway in flammation in- bronchial asthma [ J ]. Auris Nasus Larynx, 2011,38 ( 5 ) : 555, 563.
  • 8Bateman ED,Hurd SS,Barnes PJ,et al.Global strategy for asthma management and prevention:GINA executive stlmmary[J].Eur Respir J,2008,31(1):143.
  • 9Zhang WJ,Hufnagl P,Binder BR,et al.Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappa B activation and adhesion molecule expression[J].Thromb Haemost,2003,90(5):904-914.
  • 10Yuan X,Sun S,Wang S,et al.Effects of astragalosideⅣon IFNgamma level and prolonged airway dysfunction in a murine model of chronic asthma[J].Planta Med,2011,77(4):328-333.

引证文献8

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部